Regentis Biomaterials Ltd. plans to list on the NYSE American under the symbol RGNT, at $10.00 to $12.00 a share. It filed a Form F-1 registration statement for an initial public offering on March 11, 2025. As of November 6, 2026, its registration is on file (Form F-1, July 8, 2026).
Sell to companies like Regentis Biomaterials Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · What it is: Registration statement filed (foreign issuer) · F-1
- · What it is: Request to withdraw a registration (Form F-1) · RW
- · What it is: Registration statement amended (foreign issuer) · F-1/A
- · What it is: Registration statement filed (foreign issuer) · F-1
- · What it is: Registration statement amended (foreign issuer) · F-1/A
Regentis Biomaterials Ltd. filed a Form F-1 registration statement for an initial public offering on 2025-03-11. It has amended it 7 times. As of its latest filing, on 2026-07-08, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
Also on the record for Regentis Biomaterials Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | Stake report, Schedule 13G, by Rosalind Advisors, Inc. | 9.9% of the class | 5%+ stakes | Source |
| June 25, 2026 | Form D, private offering | $6.50M sold | Form D page | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Dr. Ehud Geller | 23.2% of the class | 5%+ stakes | Source |
Check before you invest in Regentis Biomaterials Ltd.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Regentis Biomaterials Ltd. and the records around it.
Regentis Biomaterials Ltd. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Jun 2026
- Who owns it
Companies that share a holder
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
Also filing to list on the NYSE American
IPO filings on the NYSE American in Q3 2026, newest first.
- KNOREX LTD. (Sep 2026)
- Skubbs Holdings Ltd (Sep 2026)
- NextBoat Inc. (Aug 2026)
- IMC Rare Earths Ltd (Aug 2026)
- SunScout Holding Ltd (Aug 2026)
Watch Regentis Biomaterials Ltd.
Get an email when Regentis Biomaterials Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Regentis Biomaterials Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Regentis Biomaterials Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Regentis Biomaterials Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our Ordinary Shares are listed on the NYSE American under the symbol “RGNT”.From the F-1 filed 2026-07-08
Price range
This is a firm commitment initial public offering of ordinary shares, no par value, or Ordinary Shares, of Regentis Biomaterials Ltd. The anticipated initial public offering price will be between $10.00 and $12.00 per Ordinary Share.From the F-1/A filed 2025-10-24
Use of proceeds
We intend to use the net proceeds of such Offered Warrant exercise, if any, for the continued development of our Gelrin platform, continuation of clinical studies, scaling up operations and general corporate purposes.From the F-1 filed 2026-07-08
Revenue
Net revenues of $55.7 for MACI in third quarter of 2025 (4) https://www.smith-nephew.com/en/news/2024/01/10/20240110---sn-completes-acquisition-of-novel-cartilage-regeneration.From the F-1 filed 2026-05-01
Net loss or income
We have incurred losses in each year since our inception (except for 2024 as a result of a one-time research and development grant which resulted in a one-time income), including net income of $4.8 million and a loss of $4.1 million for the years ended December 31, 2024 and 2023, respectively, and a loss of $3.2 million and net income of $7.2 million for the six months ended June 30, 2025 and 2024 respectively.From the F-1/A filed 2025-10-24
Withdrawal
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Regentis Biomaterials Ltd., a corporation existing under the laws of Israel (the “Company”), hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) consent to the withdrawal, effective as of the date hereof, or at the earliest practicable date hereafter, of the Company’s Registration Statement on Form F-1 (File No. 333-295510), originally filed on May 1, 2026, as amended on June 9, 2026 (together with all exhibits thereto, the “Registration Statement”).From the RW filed 2026-06-15
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-11-21 | Request to withdraw a registration (Form F-1) | RW |
| 2025-03-11 | Registration statement filed (foreign issuer) | F-1 |
| 2025-05-05 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-05-19 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-07-07 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-09-09 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-09-30 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-10-24 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-05-01 | Registration statement filed (foreign issuer) | F-1 |
| 2026-06-09 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-06-15 | Request to withdraw a registration (Form F-1) | RW |
| 2026-07-08 | Registration statement filed (foreign issuer) | F-1 |
Tools for this story
Each opens in a new tab, filled in for Regentis Biomaterials Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.